BRCA1 and esophageal squamous cell carcinoma: In total, 18% of ESCC patients displayed early-occurring BRCA1-2 mutations, associated with high levels of the mutational signature 3; knockdown of BRCA1-2 strongly increased the sensitivity of ESCC cells to cisplatin.